Skip to main content
194 results

It is not a tick box template – all consultations with patients should be approached holistically and tailored specifically to the patient’s needs, requirements and other co-morbidities and situations.

We have issued pragmatic guidance for the routine and crisis management of patients with asthma and COPD during the UK Covid-19 epidemic.

Can Only Plan Daily - COPD is a serious disease needing the right diagnosis and treatment with the person’s need sitting front and centre.

Very Brief Advice (VBA) is our most practical tool to trigger a quit attempt, with structured behavioural support and medical treatment being the best method of quitting and ideally these are provided by stop smoking practitioners.

ASK : ADVISE : ACT Using VBA does not depend on the person's readiness to quit and you do not need to assess it before you start Very Brief Advice or VBA is a simple and

Tobacco dependency is a long-term relapsing condition that usually starts in childhood This tobacco dependency pragmatic guide is a practical, immediately implementable, evidence-based framework to enable healthcare professionals to routinely identify smokers, encourage a quit attempt a

Asthma Guidelines in Practice – A PCRS Consensus is a practical and pragmatic guide for healthcare professionals working in primary and intermediate care.  This guide was commissioned to provide clarity on aspects of diagnosis, management and monitoring of asthma that are uncertain

Maintenance and reliever therapy (MART) is a combined treatment system for asthma where a single, combined inhaler is used for both maintenance and reliever purposes, instead of having separate preventer (brown) and reliever (blue) inhalers.

Maintenance and reliever therapy (MART) is a treatment for asthma where a single combined inhaler is used for both maintenance and reliever purposes, instead of having separate preventer (brown) and reliever (blue) inhalers. 

A new interactive resource to facilitate the delivery of holistic care.Thi

In this article, the authors review evidence, guidance and current practice to provide a consensus approach to calculating and interpreting peak expiratory flow rate (PEFR) variability and reversibility from peak flow diary recordings for asthma diagnosis.

In 2023, the Medicines and Healthcare Products Regulatory Agency (MHRA) approved the use of a dual (Inhaled corticosteroid/ Formoterol) combination treatment to be used as a reliever therapy for people aged 12 and over with the therapy choice situated early in the asthma treatment pathway as an a

NICE Diagnostic Guidance 12 (DG12); Measuring fractional exhaled nitric oxide concentration in asthma: NIOX MINO, NIOX VERO and NObreath.

NICE guidance is integral to the clinical care that we offer as Health Care Professionals (HCPs).